BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Yuanming, Lu ^a,b   Lineng, Zhang ^b   Baorong, Song ^a,b   Junjie, Peng ^a,b   Sanjun, Cai ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biomarkers; Chemosensitivity; RT PCR

Indexed keywords

BRCA1 PROTEIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHINESE; COLORECTAL CANCER; DOWN REGULATION; ERCC1 GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BLOTTING, WESTERN; BRCA1 PROTEIN; CHINA; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; REGRESSION ANALYSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84874527959     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-103     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009, 59:225-49. 10.3322/caac.20006, 19474385.
2. Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lym phocytes. Mutat Res 2000, 461:197-210. 10.1016/S0921-8777(00)00051-3, 11056291.
3. Kwon HC, Roh M, Oh S, Kim SH, Kim M, Kim JS, Kim HJ. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007, 18:504-9.
4. Park DJ, Lenz HJ. Determination of chemosensitivity in gastric cancer. Curr Opin Pharmacol 2006, 6:337-344. 10.1016/j.coph.2006.05.002, 16777480.
5. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. BRCA1 functions as a differential modulator chemotherapy-induced apoptosis. Cancer Res 2003, 63:6221-8.
6. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006, 25:5854-63. 10.1038/sj.onc.1209872, 16998500.
7. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Nat Cancer Inst 2004, 96:1659-68. 10.1093/jnci/djh312, 15547178.
8. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13:2443-9. 10.1093/hmg/ddh260, 15317748.
9. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002, 360:1007-14. 10.1016/S0140-6736(02)11087-7, 12383682.
10. Kurebayashi J, Yamamoto Y, Kurosumi M, Okubo S, Nomura T, Tanaka K, Sonoo H. Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006, 26:695-702.
11. Chambers AF, Groom AC, Macdonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865, 12154349.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.
13. Vineis G, Talaska C, Malaveille H, Bartsch T, Martone P, Sithisarankul P. Strickland. DNA adducts in urothelialcells: relationship with biomarkers of exposure to arylaminesand polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer 1996, 65:314-316.
14. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, Hemminki K. The XPD variant alleles areassociated with increased aromatic DNA adduct level and lungcancer risk. Carcinogenesis 2002, 23:599-603. 10.1093/carcin/23.4.599, 11960912.
15. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladdercancer in a case-control study. Int J Cancer 2001, 92:562-567. 10.1002/ijc.1228, 11304692.
16. Liu G, Zhou W, Christiani DC. Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 2005, 26:265-272. 10.1055/s-2005-871983, 16052427.
17. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999, 59:3968-71.
18. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998, 16:309-16.
19. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-304.
20. Heike G, Mit D, Lisa B, Nicola M, Karen M, Olaf H, Helmut EG, Wolfram M. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006, 12(5):1494-1500. 10.1158/1078-0432.CCR-05-2105, 16533773.